225 related articles for article (PubMed ID: 25286857)
21. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor.
Karlberg T; Markova N; Johansson I; Hammarström M; Schütz P; Weigelt J; Schüler H
J Med Chem; 2010 Jul; 53(14):5352-5. PubMed ID: 20565110
[TBL] [Abstract][Full Text] [Related]
22. Tankyrase-1 overexpression reduces genotoxin-induced cell death by inhibiting PARP1.
Yeh TY; Sbodio JI; Nguyen MT; Meyer TN; Lee RM; Chi NW
Mol Cell Biochem; 2005 Aug; 276(1-2):183-92. PubMed ID: 16132700
[TBL] [Abstract][Full Text] [Related]
23. Tankyrase Requires SAM Domain-Dependent Polymerization to Support Wnt-β-Catenin Signaling.
Mariotti L; Templeton CM; Ranes M; Paracuellos P; Cronin N; Beuron F; Morris E; Guettler S
Mol Cell; 2016 Aug; 63(3):498-513. PubMed ID: 27494558
[TBL] [Abstract][Full Text] [Related]
24. Structural insights into SAM domain-mediated tankyrase oligomerization.
DaRosa PA; Ovchinnikov S; Xu W; Klevit RE
Protein Sci; 2016 Sep; 25(9):1744-52. PubMed ID: 27328430
[TBL] [Abstract][Full Text] [Related]
25. Regulation of tankyrase activity by a catalytic domain dimer interface.
Fan C; Yarravarapu N; Chen H; Kulak O; Dasari P; Herbert J; Yamaguchi K; Lum L; Zhang X
Biochem Biophys Res Commun; 2018 Sep; 503(3):1780-1785. PubMed ID: 30055800
[TBL] [Abstract][Full Text] [Related]
26.
Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
[TBL] [Abstract][Full Text] [Related]
27. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
Ryan K; Bolaňos B; Smith M; Palde PB; Cuenca PD; VanArsdale TL; Niessen S; Zhang L; Behenna D; Ornelas MA; Tran KT; Kaiser S; Lum L; Stewart A; Gajiwala KS
J Biol Chem; 2021; 296():100251. PubMed ID: 33361107
[TBL] [Abstract][Full Text] [Related]
28. Pleiotropic roles of tankyrase/PARP proteins in the establishment and maintenance of human naïve pluripotency.
Zimmerlin L; Zambidis ET
Exp Cell Res; 2020 May; 390(1):111935. PubMed ID: 32151493
[TBL] [Abstract][Full Text] [Related]
29. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
30. PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification.
Langelier MF; Eisemann T; Riccio AA; Pascal JM
Curr Opin Struct Biol; 2018 Dec; 53():187-198. PubMed ID: 30481609
[TBL] [Abstract][Full Text] [Related]
31. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the structure-based rational design of TNKSIs.
Zhan P; Song Y; Itoh Y; Suzuki T; Liu X
Mol Biosyst; 2014 Nov; 10(11):2783-99. PubMed ID: 25211064
[TBL] [Abstract][Full Text] [Related]
33. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents.
Reiner T; Lacy J; Keliher EJ; Yang KS; Ullal A; Kohler RH; Vinegoni C; Weissleder R
Neoplasia; 2012 Mar; 14(3):169-77. PubMed ID: 22496617
[TBL] [Abstract][Full Text] [Related]
34. Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length.
Rippmann JF; Damm K; Schnapp A
J Mol Biol; 2002 Oct; 323(2):217-24. PubMed ID: 12381316
[TBL] [Abstract][Full Text] [Related]
35. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
36. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
[TBL] [Abstract][Full Text] [Related]
37. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.
Lehtiö L; Jemth AS; Collins R; Loseva O; Johansson A; Markova N; Hammarström M; Flores A; Holmberg-Schiavone L; Weigelt J; Helleday T; Schüler H; Karlberg T
J Med Chem; 2009 May; 52(9):3108-11. PubMed ID: 19354255
[TBL] [Abstract][Full Text] [Related]
38. Crystal structures of the catalytic domain of human PARP15 in complex with small molecule inhibitors.
Zhou X; Yang Y; Xu Q; Zhou H; Zhong F; Deng J; Zhang J; Li J
Biochem Biophys Res Commun; 2022 Sep; 622():93-100. PubMed ID: 35843099
[TBL] [Abstract][Full Text] [Related]
39. Tankyrase 2 poly(ADP-ribose) polymerase domain-deleted mice exhibit growth defects but have normal telomere length and capping.
Hsiao SJ; Poitras MF; Cook BD; Liu Y; Smith S
Mol Cell Biol; 2006 Mar; 26(6):2044-54. PubMed ID: 16507985
[TBL] [Abstract][Full Text] [Related]
40. The C. elegans gene pme-5: molecular cloning and role in the DNA-damage response of a tankyrase orthologue.
Gravel C; Stergiou L; Gagnon SN; Desnoyers S
DNA Repair (Amst); 2004 Feb; 3(2):171-82. PubMed ID: 14706351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
